Guides
How do tirzepatide and semaglutide differ at GIP and GLP-1 receptors?
Short answer
Tirzepatide activates both GIP and GLP-1 receptors. Semaglutide is a GLP-1 receptor agonist. Counting receptor types describes a mechanism. It cannot predict how an individual’s weight will change.12
What is an agonist?
An agonist activates a receptor and triggers a signal. GIP and GLP-1 are hormones made by the body. Their signals help regulate blood glucose, and GLP-1 signalling also plays a role in appetite.12
Does that mean two drugs in a tirzepatide pen?
One active molecule can interact with both receptor types. A structural study examined how the same molecule binds to each. A receptor model by itself cannot tell an individual what side effects they will experience.3
How can I check a weight comparison?
The SURMOUNT-5 registry entry specifies change in body weight at 72 weeks as the primary outcome. That gives the group comparison a measurable target. Also look at who could take part and which adverse events were recorded.4
Primary sources
- EMA, European public assessment report for Mounjaro
- EMA, European public assessment report for Wegovy
- Primary structural study of tirzepatide at two receptors (2022)
- Trial registry, SURMOUNT-5 and its prespecified outcomes
Cite this page
Fastzuleicht · Editorial team. How do tirzepatide and semaglutide differ at GIP and GLP-1 receptors? (19 November 2026). https://fastzuleicht.de/guides/gip-glp1-tirzepatide-semaglutide-receptors/